Transdermal Buprenorphine for Induction of Patients with Co-Morbid Pain

This is the second of two webinars on Medication Assisted Treatment (MAT) in primary care settings. The California Society of Addiction Medicine (CSAM) created these programs with the support of a grant from the California Department of Healthcare Services (DHCS). 

Description: This webinar will review the complexities of carrying out buprenorphine inductions among patients with co-morbid pain, and a novel approach for managing these transitions.

Webinar recorded on 3/13/2019.

PRICE/PURCHASE

ASAM and/or CSAM Members: Free
Non-Member: $50.00

You must register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and choose your purchase option (member/non-member) and click "Add to Cart." 

Credit

This enduring internet activity is directly provided by the California Society of Addiction Medicine (CSAM) with the support of a grant from the Department of Healthcare Services (DHCS). CSAM is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

PA’s, nurses, pharmacists, psychologists and therapists can earn CEU credit.

**CSAM accepts no funding from the pharmaceutical industry in creating this webinar or any of its educational programs.

Target Audience

  1. Primary Care Physician who are beginning or planning to integrate buprenorphine for the treatment of opioid dependence into their practice.
  2. Associated health professionals who work in a setting that treats opioid dependent patients. 

Learning Objectives

  1.  Describe new CDC guidelines for chronic pain management.
  2.  Describe potential risks of precipitated withdrawal in patients on chronic opioids.
  3.  Describe the risks and benefits of using transdermal buprenorphine in an induction for patients with co-morbid chronic pain and opioid use disorder.
Course summary
Available credit: 
  • 1.00 AMA Category 1
  • 1.00 Attendance
Course opens: 
03/13/2019
Course expires: 
03/16/2022
Cost:
$50.00

Soraya Azari, MD (Moderator)
Associate Professor of Medicine
Division of General Internal Medicine
University of California, San Francisco
San Francisco General Hospital

Tauheed Zaman, MD
Medical Director
Opioid Safety and Addiction Consult
San Francisco, VA Medical Center
 

Soraya Azari, Tauheed Zaman and the Planners of this activity have no relevant financial relationships to disclose

This enduring internet activity is directly provided by the California Society of Addiction Medicine (CSAM) with the support of a grant from the Department of Healthcare Services (DHCS). CSAM is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians. CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

PA’s, nurses, pharmacists, psychologists and therapists can earn CEU credit.

Available Credit

  • 1.00 AMA Category 1
  • 1.00 Attendance

Accreditation Period

Course opens: 
03/13/2019
Course expires: 
03/16/2022

Price

Cost:
$50.00
Please login or register to take this course.